文献速递骨肿瘤关节外科

原发性骨肿瘤股骨远端假体置换术中股骨柄断裂的相关因素分析

What Factors Are Associated With Stem Breakage in Distal Femoral Endoprosthetic Replacements Undertaken for Primary Bone Tumors?
PubMed 文献 · Clin Orthop Relat Res · 2023-06-27

该回顾性研究分析了2003至2020年间单中心使用GMRS假体行股骨远端置换的原发性骨肉瘤患者,92例纳入分析,5.4%发生股骨柄断裂,全部见于柄直径≤11 mm的多孔体构造组,该组断裂率16%。作者推荐使用直径>11 mm的骨水泥柄,并建议对<12 mm柄或少量骨长入者密切随访。

要点

  • 92例中5例(5.4%)发生股骨柄断裂,均见于柄直径≤11 mm的多孔体构造组(5/31,16%)。
  • 断裂患者均表现为多孔涂层体骨长入极少,中位断裂时间10年(范围2至12年),其中2例在3年内断裂。
  • 作者推荐使用直径>11 mm的GMRS骨水泥柄,较小髓腔可考虑线对线骨水泥技术或替代公司非骨水泥柄。

核心结论

  • 作者推荐使用更大直径(>11 mm)的GMRS骨水泥柄,较小髓腔可考虑线对线骨水泥法或替代公司的非骨水泥柄以实现更大直径。
  • 若必须使用直径<12 mm的柄或存在骨长入极少的证据,则应密切随访并及时检查新发症状。

研究设计与样本

  • 回顾性研究,纳入2003至2020年昆士兰骨与软组织肿瘤服务中心所有因原发性骨肉瘤行股骨远端切除并GMRS置换、随访至少2年的患者。
  • 共116例患者接受GMRS股骨远端置换,排除6.9%(8/116)未完成2年随访即死亡者;其余108例中15%(16例)在综述时已死亡但已完成2年随访且无柄断裂而纳入;另15%(16例)因过去5年未就诊且未知死亡或柄断裂而视为失访排除;最终92例纳入分析。

主要发现

  • 92例中5例(5.4%)发生股骨柄断裂。
  • 所有断裂均发生于柄直径≤11 mm的多孔体构造组,该组31例中5例断裂(16%)。
  • 所有柄断裂患者均显示多孔涂层体骨长入极少。
  • 中位断裂时间为10年(范围2至12年),5例中2例在3年内断裂。

临床怎么用

  • 作者推荐使用直径>11 mm的GMRS骨水泥柄。
  • 作者建议较小髓腔可考虑线对线骨水泥法或替代公司的非骨水泥柄以获得更大直径柄。
  • 作者建议若必须使用直径<12 mm的柄或存在骨长入极少证据,则应密切随访并及时检查新发症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The advantages of distal femoral replacement prostheses for reconstructions after tumors are well known; one such implant, the Global Modular Replacement System (GMRS), has been widely used since 2003. Although implant breakage has been reported, the frequency of this event has varied across different studies. QUESTIONS/PURPOSES: (1) What percentage of patients who underwent distal femur resection and replacement using the GMRS for primary bone tumors at one center experienced stem breakage? (2) At what timepoints did these breakages occur, and what factors were common among the stems that broke? METHODS: We performed a retrospective study of all patients who underwent distal femur resection and replacement using the GMRS for a diagnosis of primary bone sarcoma by the Queensland Bone and Soft-tissue Tumor service from 2003 to 2020 who had a minimum of 2 years of follow-up. Standard follow-up for primary bone sarcoma involves radiographic imaging of the femur at 6 weeks and 3 months postoperatively and yearly thereafter. From a chart review, we identified patients with femoral stem breakage. Patient and implant details were recorded and analyzed. A total of 116 patients had undergone a distal femoral replacement with the GMRS prosthesis for primary bone sarcoma; however, 6.9% (eight of 116 patients) died before completing the 2-year follow-up period and were excluded. Of the remaining 108 patients, 15% (16 patients) had died at the time of this review; however, given that they completed the 2-year follow-up period and did not experience stem breakage, they were included. Furthermore, 15% (16 patients) were considered lost to follow-up and excluded because they have not been seen in the past 5 years but were not known to have died or experienced stem breakage. This left 92 patients for analysis. RESULTS: Stem breakages were identified in 5.4% (five of 92) of patients. All stem breakages occurred in stem diameters 11 mm or less with a porous body construct; the percentage of patients with breakage in this group was 16% (five of 31). All patients with stem fracture demonstrated minimal ongrowth to the porous coated body. The median time to stem fracture was 10 years (range 2 to 12 years); however, two of the five stems broke within 3 years. CONCLUSION: We recommend the use of a larger-diameter GMRS cemented stem (> 11 mm), and either the line-to-line cementing method or an uncemented stem from an alternative company should be considered in order to achieve this larger stem in smaller canals. If a stem less than 12 mm in diameter must be used or there is evidence of minimal ongrowth, then close follow-up and prompt investigation of new symptoms should occur. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Carlisle E, Steadman P, Lowe M, et al. What Factors Are Associated With Stem Breakage in Distal Femoral Endoprosthetic Replacements Undertaken for Primary Bone Tumors? Clin Orthop Relat Res. 2023. PMID: 37368003. doi:10.1097/CORR.0000000000002746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。